Handelsbanken Fonder AB Takes Position in Alumis Inc. $ALMS

Handelsbanken Fonder AB bought a new stake in shares of Alumis Inc. (NASDAQ:ALMS) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 36,400 shares of the company’s stock, valued at approximately $1,024,000.

A number of other institutional investors have also recently added to or reduced their stakes in ALMS. Ieq Capital LLC increased its holdings in Alumis by 4.1% in the 4th quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock worth $170,000 after acquiring an additional 690 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Alumis by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after purchasing an additional 979 shares in the last quarter. Strs Ohio grew its position in shares of Alumis by 300.0% in the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after purchasing an additional 1,500 shares during the period. ProShare Advisors LLC grew its position in shares of Alumis by 12.4% in the fourth quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock valued at $143,000 after purchasing an additional 1,618 shares during the period. Finally, KBC Group NV purchased a new stake in shares of Alumis during the first quarter worth about $42,000.

Insider Buying and Selling at Alumis

In other news, insider David M. Goldstein sold 2,596 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $68,456.52. Following the transaction, the insider directly owned 30,970 shares in the company, valued at $816,678.90. The trade was a 7.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Roy C. Hardiman sold 2,692 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $70,988.04. Following the completion of the sale, the insider owned 207,746 shares of the company’s stock, valued at $5,478,262.02. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 19,953 shares of company stock worth $534,311. 33.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms recently weighed in on ALMS. Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. Morgan Stanley reiterated an “overweight” rating and issued a $39.00 price objective on shares of Alumis in a report on Friday, May 15th. HC Wainwright reiterated a “neutral” rating and set a $25.00 price objective on shares of Alumis in a research note on Friday, August 14th. Guggenheim increased their target price on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, May 15th. Finally, Wall Street Zen downgraded Alumis from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $40.30.

Alumis Stock Down 3.6%

Shares of NASDAQ ALMS opened at $23.99 on Thursday. The firm has a 50-day simple moving average of $26.49 and a 200-day simple moving average of $25.22. The stock has a market capitalization of $3.06 billion, a price-to-earnings ratio of -6.22 and a beta of -0.69. Alumis Inc. has a 52 week low of $3.76 and a 52 week high of $31.35.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%.The business had revenue of $1.66 million for the quarter, compared to analyst estimates of $3.65 million. As a group, equities research analysts expect that Alumis Inc. will post -2.95 EPS for the current year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.